Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01399-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Mahmoud Tareq Abdelwahab und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Clofazimine, Diarylquinolines, Nitroimidazoles, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Swedish Foundation for International Cooperation in Research and Higher Education, South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation.
Abstract (Originalsprache)
Drug resistance (DR) poses a critical challenge to global efforts to manage tuberculosis (TB). Limited information is available on the combined cardiotoxicity of bedaquiline (BDQ), pretomanid (Pa), and clofazimine (CFZ), key drugs in current DR-TB treatment regimens. All of those prolong the QT interval. We aimed to describe this interaction to predict possible toxicities with established and novel dosing regimens to identify patients at higher risk of QT prolongation. The data for this analysis were obtained from an early-bactericidal activity study in drug-susceptible-TB of several TB drugs. We developed a competitive interaction model to evaluate combined concentration-QTc effect of all three drugs. The model was developed using ECG-matched PK measurements (105 patients, 2,062 observations). The model identified a maximum QT increase by all three drugs of 44.5 ms with respective EC50 values for BDQ, Pa, and CFZ of 0.57, 0.903, and 26.9 mg/L. For patients aged 70 years with non-black ancestry, at risk of increased BDQ exposure, simulations showed that 39.1% had a drug-induced QT change >30 ms after the loading period; this was 29.4% for following BDQ 400 mg daily regimen (part of UNITE4TB program). Reassuringly, no simulations resulted in a QTcF >500 ms, and less than 1% exceeded 480 ms or a change from baseline of >60 ms. We present a joint concentration-QT model of BDQ, Pa, and CFZ. The competitive interaction model serves as a tool to predict possible combined exposure-induced QT prolongation of these drugs in different dosing regimen and identify patients at high risk of significant QT-prolongation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Task, Bellville, South Africa.
- Global Alliance for TB Drug Development, New York, New York, USA.
- Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Cape Town, South Africa.
ORCID-Profile: Mahmoud Tareq Abdelwahab, Elin M Svensson, Gary Maartens, Paolo Denti
Förderung
- Wellcome Trust
- Swedish Foundation for International Cooperation in Research and Higher Education
- South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation
- NRF incentive funding
Zitieren
APA
Abdelwahab, M. T., Svensson, E. M., Diacon, A. H., Conradie, A., Olugbosi, M., Dawson, R., Maartens, G., & Denti, P. (2026). Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01399-25
Vancouver
Abdelwahab MT, Svensson EM, Diacon AH, Conradie A, Olugbosi M, Dawson R, et al. Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01399-25
BibTeX
@article{Abdelwahab2026,
author = {Abdelwahab, Mahmoud Tareq and Svensson, Elin M and Diacon, Andreas H and Conradie, Almarie and Olugbosi, Morounfolu and Dawson, Rodney and Maartens, Gary and Denti, Paolo},
title = {Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01399-25}
}
EUVIMED